Cargando…

The Respimat(®) Soft Mist Inhaler: Implications of Drug Delivery Characteristics for Patients

Successful treatment for respiratory diseases relies on effective delivery of medication to the lungs using an inhalation device. Different inhalers have distinct characteristics affecting drug administration and patient adherence, which can impact clinical outcomes. We report on the development of...

Descripción completa

Detalles Bibliográficos
Autores principales: Iwanaga, Takashi, Tohda, Yuji, Nakamura, Shuhei, Suga, Yasunori
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6800401/
https://www.ncbi.nlm.nih.gov/pubmed/31377981
http://dx.doi.org/10.1007/s40261-019-00835-z
_version_ 1783460434845630464
author Iwanaga, Takashi
Tohda, Yuji
Nakamura, Shuhei
Suga, Yasunori
author_facet Iwanaga, Takashi
Tohda, Yuji
Nakamura, Shuhei
Suga, Yasunori
author_sort Iwanaga, Takashi
collection PubMed
description Successful treatment for respiratory diseases relies on effective delivery of medication to the lungs using an inhalation device. Different inhalers have distinct characteristics affecting drug administration and patient adherence, which can impact clinical outcomes. We report on the development of the Respimat(®) soft mist inhaler (SMI) and compare key attributes with metered-dose inhalers (MDIs) and dry powder inhalers (DPIs). The Respimat SMI, a pocket-sized device generating a single-breath, inhalable aerosol, was designed to enhance drug delivery to the lungs, reduce the requirements for patient coordination and inspiratory effort, and improve the patients’ experience and ease of use. The drug deposition profile with Respimat SMI is favorable compared with MDIs and DPIs, with higher drug deposition to the lung and peripheral airways. The slow velocity and long spray duration of the Respimat SMI aerosol also aid patient coordination. Clinical equivalence has been demonstrated for maintenance treatment of chronic obstructive pulmonary disease using once-daily tiotropium between Respimat SMI (5 µg) and HandiHaler DPI (18 µg). In comparative studies, patients preferred Respimat SMI to MDIs and DPIs; they reported that Respimat SMI was easy to use and felt the inhaled dose was delivered. The Respimat SMI, designed to generate a slow-moving and fine mist, is easy to use and effectively delivers drug treatment to the lungs. The patient-centered design of Respimat SMI improved patient satisfaction, and may help to promote long-term adherence and improve clinical outcomes with asthma and chronic obstructive pulmonary disease.
format Online
Article
Text
id pubmed-6800401
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Springer International Publishing
record_format MEDLINE/PubMed
spelling pubmed-68004012019-11-01 The Respimat(®) Soft Mist Inhaler: Implications of Drug Delivery Characteristics for Patients Iwanaga, Takashi Tohda, Yuji Nakamura, Shuhei Suga, Yasunori Clin Drug Investig Review Article Successful treatment for respiratory diseases relies on effective delivery of medication to the lungs using an inhalation device. Different inhalers have distinct characteristics affecting drug administration and patient adherence, which can impact clinical outcomes. We report on the development of the Respimat(®) soft mist inhaler (SMI) and compare key attributes with metered-dose inhalers (MDIs) and dry powder inhalers (DPIs). The Respimat SMI, a pocket-sized device generating a single-breath, inhalable aerosol, was designed to enhance drug delivery to the lungs, reduce the requirements for patient coordination and inspiratory effort, and improve the patients’ experience and ease of use. The drug deposition profile with Respimat SMI is favorable compared with MDIs and DPIs, with higher drug deposition to the lung and peripheral airways. The slow velocity and long spray duration of the Respimat SMI aerosol also aid patient coordination. Clinical equivalence has been demonstrated for maintenance treatment of chronic obstructive pulmonary disease using once-daily tiotropium between Respimat SMI (5 µg) and HandiHaler DPI (18 µg). In comparative studies, patients preferred Respimat SMI to MDIs and DPIs; they reported that Respimat SMI was easy to use and felt the inhaled dose was delivered. The Respimat SMI, designed to generate a slow-moving and fine mist, is easy to use and effectively delivers drug treatment to the lungs. The patient-centered design of Respimat SMI improved patient satisfaction, and may help to promote long-term adherence and improve clinical outcomes with asthma and chronic obstructive pulmonary disease. Springer International Publishing 2019-08-03 2019 /pmc/articles/PMC6800401/ /pubmed/31377981 http://dx.doi.org/10.1007/s40261-019-00835-z Text en © The Author(s) 2019 Open AccessThis article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
spellingShingle Review Article
Iwanaga, Takashi
Tohda, Yuji
Nakamura, Shuhei
Suga, Yasunori
The Respimat(®) Soft Mist Inhaler: Implications of Drug Delivery Characteristics for Patients
title The Respimat(®) Soft Mist Inhaler: Implications of Drug Delivery Characteristics for Patients
title_full The Respimat(®) Soft Mist Inhaler: Implications of Drug Delivery Characteristics for Patients
title_fullStr The Respimat(®) Soft Mist Inhaler: Implications of Drug Delivery Characteristics for Patients
title_full_unstemmed The Respimat(®) Soft Mist Inhaler: Implications of Drug Delivery Characteristics for Patients
title_short The Respimat(®) Soft Mist Inhaler: Implications of Drug Delivery Characteristics for Patients
title_sort respimat(®) soft mist inhaler: implications of drug delivery characteristics for patients
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6800401/
https://www.ncbi.nlm.nih.gov/pubmed/31377981
http://dx.doi.org/10.1007/s40261-019-00835-z
work_keys_str_mv AT iwanagatakashi therespimatsoftmistinhalerimplicationsofdrugdeliverycharacteristicsforpatients
AT tohdayuji therespimatsoftmistinhalerimplicationsofdrugdeliverycharacteristicsforpatients
AT nakamurashuhei therespimatsoftmistinhalerimplicationsofdrugdeliverycharacteristicsforpatients
AT sugayasunori therespimatsoftmistinhalerimplicationsofdrugdeliverycharacteristicsforpatients
AT iwanagatakashi respimatsoftmistinhalerimplicationsofdrugdeliverycharacteristicsforpatients
AT tohdayuji respimatsoftmistinhalerimplicationsofdrugdeliverycharacteristicsforpatients
AT nakamurashuhei respimatsoftmistinhalerimplicationsofdrugdeliverycharacteristicsforpatients
AT sugayasunori respimatsoftmistinhalerimplicationsofdrugdeliverycharacteristicsforpatients